Therefore, the injected formulation (injected mass and molar activity) of PARP-targeting radiopharmaceuticals may have a direct influence on their distribution and accumulation in tumour and organs, especially spleen and liver, which have higher expression levels of PARP1, 2 and 3 (The European Bioinformatics Institute: www.ebi.ac.uk). The gene discussed is PARP1; the disease is neoplasm.